STRO-001

Sutro Biopharma, in collaboration with Merck, dosed the first patient in a Phase 1 study for a novel cytokine derivative therapeutic targeting cancer, triggering a $10 million payment to Sutro. This milestone highlights the synergy between Merck's immuno-oncology expertise and Sutro's biologics engineering capabilities.

STRO-001, a novel CD74-targeting ADC, shows promise in treating B-cell NHL with a 25% clinical benefit rate in a Phase 1 study. It's well-tolerated, with most AEs being grade 1 or 2, and no ocular or neuropathy toxicity observed. The study continues dose escalation, with next levels at 2.5 mg/kg and 3.5 mg/kg.

STRO-001, a novel antibody-drug conjugate targeting CD74, shows promising anti-tumor activity in multiple myeloma (MM) models. It effectively reduces tumor burden and prolongs survival in MM xenograft models, with dose-dependent efficacy and reversible B-cell and monocyte depletion in cynomolgus monkeys. CD74 expression is prevalent in MM, making it a viable therapeutic target.